The current study was designed to assess the impact of ExoPTEN on the motor, reflex, and sensory recovery of rats, following full transection (i.e. complete severing) of the spinal cord. Read More >>>
NurExone has established itself as a unique company by possessing both a product in development, ExoPTEN, and an advanced platform for the production and loading of exosomes. This combination aims to position the company ahead of its competitors in terms of effectiveness and efficiency. Read More >>>
The Patent discloses and claims groundbreaking inventions and methods in exosome technology, such as the pharmaceutical compositions comprising extracellular vesicles including exosomes, loaded with an exogenous inhibitor of phosphatase and tensin homolog (PTEN) inhibitor as well as a method for treating neuronal injury or damage, including intranasal administration. Read More
It has been an outstanding year with significant scientific and business developments! We move forward to a greater achievements and accomplishments! Read More …
We started our journey to provide much-needed therapy for people who have suffered spinal cord injuries and have accomplished very significant achievements in 2022. As we progress with developing our underlying technology, the awareness of a greater picture has intensified. The same technologies and science that will serve NurExone may
The Company agreed to settle debts in the aggregate amount of CAD$46,523.69 with the issuance of 122,430 common shares of the Company at the market price on November 24, 2022 of CAD$0.38 per share. These debts were incurred prior to the recent Reverse Takeover Transaction following which NurExone began trading
Company’s analysis indicates the successful achievement of its proprietary loading technology for producing exosome-based therapies NurExone is providing an updated release to the previously disseminated release from yesterday to replace several sentences and figures that were included in error. Calgary, Alberta–(Newsfile Corp. – December 1, 2022) – NurExone Biologic Inc.
“Obtaining U.S. FDA approval for our drug platform remains a priority for NurExone and we intend to continue working towards expediting this process by submitting a Pre-IND meeting request,” said Dr. Lior Shaltiel, CEO of NurExone. “In addition to pursuing our regulatory objective, we are advancing other areas of our business, including securing
Calgary, Alberta–(Newsfile Corp. – November 8, 2022) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or “EnerSpar”) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has completed its securities for debt settlements, previously announced by
Prior to submission of a New Investigational Drug (IND) application, in September 2022, the Company submitted a request for an Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) meeting, which is an informal, non-binding meeting that is offered by the U.S. FDA to companies at an early stage
